spacer
home > ict > spring 2018 > exponential developments
PUBLICATIONS
International Clinical Trials

Exponential Developments

“The expected exposure in humans at a dose to be given, in comparison to the exposure at which certain effects were observed in animals or earlier in the study in humans, is considered more relevant than the relative dose levels between animals and humans,” claims the first-in-human (FIH) guidance.

In July 2017, the EMA revised its guidance on FIH clinical trials, providing strategies to identify and mitigate risks for trial participants. This article explores how modern clinical study strategies can be utilised in early phase studies to not only satisfy the new regulatory risk mitigation guidance principles, but also incorporate efficiencies in study design and certainty of decision-making. The purpose of this article is not to restate information that has been provided in earlier FIH guidance documents, but to highlight the new recommendations being suggested.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bradley Joblin has a doctorate from the University of Zurich, Switzerland. Having held senior management and director positions in clinical research at the headquarters of global pharmaceutical companies and smaller biotechnology companies, his experience is in clinical study implementation, early and late phase clinical study design, and clinical development strategy. Brad founded his own company providing clinical study and development advice to the clinical research community including biotech companies and medical research institutes. He joined Q-Pharm at the start of 2017 to offer scientific oversight and management within Q-Pharm, as well as study design and development strategies to clients.
spacer
Bradley Joblin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

New offices at leading science hub support the Company’s rapid growth following recent investment New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement